European Market Access Checklist

This checklist, derived from specialist knowledge of the European Health Technology Assessment (HTA) systems and pricing environments, is designed to help biotechs in Phase 1-2 to identify and close critical strategic knowledge gaps and related evidence gaps that can cause costly delays and suboptimal reimbursement.

Your ability to execute this checklist is a direct measure of your “Market Access preparedness” at this stage of development. This type of readiness can provide valuable commercial insights and a strategy foundation to presented to a partner or lincensee.

A “No” on any item below could present a risk to European partnering and commercial success, or another item to add to your market access roadmap. A free consultation can help clarify this in the context of the global product strategy.